Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Baylor Scott and White

Neither a doctor nor a teaching hospital

Research payments

$1,506,558

96 payments

Through program year 2025, Baylor Scott and White is reported as receiving $1,506,558 in research payments, across 96 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $159,408 15
2024 Research $254,857 24
2023 Research $478,640 28
2022 Research $251,349 7
2021 Research $269,357 3
2020 Research $92,946 19

Breakdown

Who paid Research payments · program years 2020–2025
  1. Alnylam Pharmaceuticals Inc. $573,684 39 payments
  2. Merck Sharp & Dohme Corporation $543,127 30 payments
  3. GlaxoSmithKline, LLC. $242,702 4 payments
  4. Teleflex LLC $65,433 3 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $46,201 19 payments
  6. Madrigal Pharmaceuticals $35,412 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis (ATTR Amyloidosis) With Cardiomyopathy $284,816 26 payments
  2. A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab MK-3475 plus Binimetinib alone or the Combination of Pembrolizumab plus Chemotherapy with or without Binimetinib in Participants with Metastatic Colorectal Cancer KEYNOTE-651 $274,498 26 payments
  3. Expanded Access Protocol to Provide Patisiran to Patients With Transthyretin-mediated Amyloidosis With Cardiomyopathy $267,360 12 payments
  4. Establishing Outcomes of Once-Daily Ics/Laba/Lama Plus PRN Respiratory $242,702 4 payments
  5. A Randomized Double-blinded Placebo-controlled Trial to Assess the Effect of a Progestin on Frequent and,or Prolonged Bleeding with Nexplanon $223,859 2 payments
  6. Xlcad Clinical Registry $65,433 3 payments
  7. A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab MK-3475 plus Binimetinib alone or the Combination of Pembrolizumab plus Chemotherapy with or without Binimetinib in Participants with Metastatic Colorectal Cancer KEYNOTE-651 $44,771 2 payments
  8. PILOT STUDY - screening for advanced Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) among adults with type 2 diabetes (T2DM) $35,412 1 payment
  9. DAROL: Darolutamide Observational Study in castration resistant prostate cancer patients $25,385 12 payments
  10. Patisiran US-only Expanded Access Program $21,507 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record